{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T23:52:07Z","timestamp":1794095527514,"version":"4.8.0"},"reference-count":131,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2020,4,20]]},"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:p>The concept of \u2018idiopathic\u2019 Parkinson\u2019s disease (PD) as a single entity has been challenged with the identification of several clinical subtypes, pathogenic genes and putative causative environmental agents. In addition to classic motor symptoms, non-motor manifestations (such as rapid eye movement sleep disorder, anosmia, constipation and depression) appear at prodromic\/premotor stage and evolve, along with cognitive impairment and dysautonomia, as the disease progresses, often dominating the advanced stages of the disease. The key molecular pathogenic mechanisms include \u03b1-synuclein misfolding and aggregation, mitochondrial dysfunction, impairment of protein clearance (associated with deficient ubiquitin-proteasome and autophagy-lysosomal systems), neuroinflammation and oxidative stress. The involvement of dopaminergic as well as noradrenergic, glutamatergic, serotonergic and adenosine pathways provide insights into the rich and variable clinical phenomenology associated with PD and the possibility of alternative therapeutic approaches beyond traditional dopamine replacement therapies.<\/jats:p>\n                  <jats:p>One of the biggest challenges in the development of potential neuroprotective therapies has been the lack of reliable and sensitive biomarkers of progression. Immunotherapies such as the use of vaccination or monoclonal antibodies directed against aggregated, toxic \u03b1-synuclein.as well as anti-aggregation or protein clearance strategies are currently investigated in clinical trials. The application of glucagon-like peptide one receptor agonists, specific PD gene target agents (such as GBA or LRRK2 modifiers) and other potential disease modifying drugs provide cautious optimism that more effective therapies are on the horizon. Emerging therapies, such as new symptomatic drugs, innovative drug delivery systems and novel surgical interventions give hope to patients with PD about their future outcomes and prognosis.<\/jats:p>","DOI":"10.1136\/jnnp-2019-322338","type":"journal-article","created":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T17:23:20Z","timestamp":1592933000000},"page":"795-808","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1121,"title":["Parkinson\u2019s disease: etiopathogenesis and treatment"],"prefix":"10.1136","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4129-3674","authenticated-orcid":false,"given":"Joseph","family":"Jankovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eng King","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,6,23]]},"reference":[{"key":"2024120318500622000_91.8.795.1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2007.131045"},{"key":"2024120318500622000_91.8.795.2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27115"},{"key":"2024120318500622000_91.8.795.3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.22360"},{"key":"2024120318500622000_91.8.795.4","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.3299"},{"key":"2024120318500622000_91.8.795.5","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30295-3"},{"key":"2024120318500622000_91.8.795.6","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26527"},{"key":"2024120318500622000_91.8.795.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2017.12.007"},{"key":"2024120318500622000_91.8.795.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2017.07.020"},{"key":"2024120318500622000_91.8.795.9","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-179006"},{"key":"2024120318500622000_91.8.795.10","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5321.2045"},{"key":"2024120318500622000_91.8.795.11","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410400513"},{"key":"2024120318500622000_91.8.795.12","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2017.1323881"},{"key":"2024120318500622000_91.8.795.13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1478"},{"key":"2024120318500622000_91.8.795.14","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26424"},{"key":"2024120318500622000_91.8.795.15","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.644"},{"key":"2024120318500622000_91.8.795.16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fneur.2018.00455","article-title":"On cell loss and selective vulnerability of neuronal populations in Parkinson\"s disease","volume":"19","author":"Gigu\u00e8re","year":"2018","journal-title":"Front Neurol"},{"key":"2024120318500622000_91.8.795.17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006926"},{"key":"2024120318500622000_91.8.795.18","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2015.236"},{"key":"2024120318500622000_91.8.795.19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrneurol.2017.27","article-title":"Cognitive decline in Parkinson disease","volume":"13","author":"Aarsland","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"2024120318500622000_91.8.795.20","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2018-318275"},{"key":"2024120318500622000_91.8.795.21","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25273"},{"key":"2024120318500622000_91.8.795.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2018.09.011"},{"key":"2024120318500622000_91.8.795.23","doi-asserted-by":"publisher","DOI":"10.1002\/mds.24996"},{"key":"2024120318500622000_91.8.795.24","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/nrdp.2017.13","article-title":"Parkinson disease","volume":"3","author":"Poewe","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2024120318500622000_91.8.795.25","doi-asserted-by":"publisher","DOI":"10.1002\/MDS.27802"},{"key":"2024120318500622000_91.8.795.26","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(16)30230-7"},{"key":"2024120318500622000_91.8.795.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2019.08.002"},{"key":"2024120318500622000_91.8.795.28","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2019.00894","article-title":"Bioenergetics and autophagic imbalance in patients-derived cell models of Parkinson disease supports systemic dysfunction in neurodegeneration","volume":"13","author":"Gonz\u00e1lez-Casacuberta","year":"2019","journal-title":"Front Neurosci"},{"key":"2024120318500622000_91.8.795.29","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax3769"},{"key":"2024120318500622000_91.8.795.30","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.6233"},{"key":"2024120318500622000_91.8.795.31","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-018-3522-z"},{"key":"2024120318500622000_91.8.795.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.04.010"},{"key":"2024120318500622000_91.8.795.33","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006786"},{"key":"2024120318500622000_91.8.795.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2018.07.009"},{"key":"2024120318500622000_91.8.795.35","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.4377"},{"key":"2024120318500622000_91.8.795.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2019.06.017"},{"key":"2024120318500622000_91.8.795.37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151841","article-title":"Association between Parkinson\"s disease and cigarette smoking, rural living, well-water consumption, farming and pesticide use: systematic review and meta-analysis","volume":"11","author":"Breckenridge","year":"2016","journal-title":"PLoS One"},{"key":"2024120318500622000_91.8.795.38","doi-asserted-by":"publisher","DOI":"10.1016\/j.yrtph.2018.05.005"},{"key":"2024120318500622000_91.8.795.39","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-018-1187-0","article-title":"Is traumatic brain injury a risk factor for neurodegeneration? A meta-analysis of population-based studies","volume":"18","author":"Huang","year":"2018","journal-title":"BMC Neurol"},{"key":"2024120318500622000_91.8.795.40","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000879"},{"key":"2024120318500622000_91.8.795.41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173731","article-title":"Serum uric acid levels in patients with Parkinson\u2019s disease: A meta-analysis","volume":"12","author":"Wen","year":"2017","journal-title":"PLoS One"},{"key":"2024120318500622000_91.8.795.42","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25292"},{"key":"2024120318500622000_91.8.795.43","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27053"},{"key":"2024120318500622000_91.8.795.44","first-page":"274","article-title":"The genetic architecture of Parkinson\"s disease","volume":"14","author":"Blauwendraat","year":"2019","journal-title":"Lancet Neurol"},{"key":"2024120318500622000_91.8.795.45","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30320-5"},{"key":"2024120318500622000_91.8.795.46","unstructured":"Senkevich K , Gan-Or Z . Autophagy lysosomal pathway dysfunction in Parkinson\"s disease; evidence from human genetics. Parkinsonism Relat Disord 2019:30491\u20132."},{"key":"2024120318500622000_91.8.795.47","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14108"},{"key":"2024120318500622000_91.8.795.48","doi-asserted-by":"crossref","DOI":"10.1126\/science.1090278","article-title":"-Synuclein Locus Triplication Causes Parkinson\"s Disease","volume":"302","author":"Singleton","year":"2003","journal-title":"Science"},{"key":"2024120318500622000_91.8.795.49","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.4.533"},{"key":"2024120318500622000_91.8.795.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2018.11.016"},{"key":"2024120318500622000_91.8.795.51","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70117-0"},{"key":"2024120318500622000_91.8.795.52","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0901281"},{"key":"2024120318500622000_91.8.795.53","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.1274"},{"key":"2024120318500622000_91.8.795.54","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.1364"},{"key":"2024120318500622000_91.8.795.55","unstructured":"Blauwendraat C , Reed X , Krohn L , et al . Genetic modifiers of risk and age at onset in GBA associated Parkinson\"s disease and Lewy body dementia. Brain 2019."},{"key":"2024120318500622000_91.8.795.56","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.9.1232"},{"key":"2024120318500622000_91.8.795.57","doi-asserted-by":"publisher","DOI":"10.1007\/s40142-017-0116-7"},{"key":"2024120318500622000_91.8.795.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2019.08.002"},{"key":"2024120318500622000_91.8.795.59","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27823"},{"key":"2024120318500622000_91.8.795.60","doi-asserted-by":"crossref","DOI":"10.1038\/s41582-020-0344-4","article-title":"Parkinson disease and the immune system - associations, mechanisms and therapeutics","author":"Tan","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"2024120318500622000_91.8.795.61","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27556"},{"key":"2024120318500622000_91.8.795.62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2019.12.001"},{"key":"2024120318500622000_91.8.795.63","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27372"},{"key":"2024120318500622000_91.8.795.64","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008699"},{"key":"2024120318500622000_91.8.795.65","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410440724"},{"key":"2024120318500622000_91.8.795.66","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.02.024"},{"key":"2024120318500622000_91.8.795.67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0809335"},{"key":"2024120318500622000_91.8.795.68","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27534"},{"key":"2024120318500622000_91.8.795.69","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27738"},{"key":"2024120318500622000_91.8.795.70","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2018.1487"},{"key":"2024120318500622000_91.8.795.71","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01104-1"},{"key":"2024120318500622000_91.8.795.72","article-title":"The narrowing path for nilotinib and other potential disease-modifying therapies for Parkinson disease","author":"Espay","year":"2019","journal-title":"JAMA Neurol"},{"key":"2024120318500622000_91.8.795.73","doi-asserted-by":"crossref","unstructured":"Ding X , Ren F . Leucine-rich repeat kinase 2 inhibitors: a patent review(2014-present). Expert Opin Ther Pat 2020:1\u201312.","DOI":"10.1080\/13543776.2020.1729354"},{"key":"2024120318500622000_91.8.795.74","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2019.4611","article-title":"Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations","volume":"77","author":"Mullin","year":"2020","journal-title":"JAMA Neurol"},{"key":"2024120318500622000_91.8.795.75","doi-asserted-by":"crossref","first-page":"e1487","DOI":"10.1212\/WNL.0000000000007173","article-title":"Increased dose of carbidopa with levodopa and entacapone improves \u201coff\u201d time in a randomized trial","volume":"92","author":"Trenkwalder","year":"2019","journal-title":"Neurology"},{"key":"2024120318500622000_91.8.795.76","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25364"},{"key":"2024120318500622000_91.8.795.77","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2019.06.025"},{"key":"2024120318500622000_91.8.795.78","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2019.06.001"},{"key":"2024120318500622000_91.8.795.79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033447"},{"key":"2024120318500622000_91.8.795.80","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809983"},{"key":"2024120318500622000_91.8.795.81","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2013.08.017"},{"key":"2024120318500622000_91.8.795.82","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70025-5"},{"key":"2024120318500622000_91.8.795.83","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26485"},{"key":"2024120318500622000_91.8.795.84","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23524"},{"key":"2024120318500622000_91.8.795.85","doi-asserted-by":"crossref","unstructured":"Rosebraugh M , Kym P , Liu W , et al . A Novel Levodopa\/Carbidopa Prodrug (ABBV-951) 24-Hour Continuous Subcutaneous Infusion Treatment for Parkinson\u2019s Disease. Neurology 2019;92.","DOI":"10.1212\/WNL.92.15_supplement.P3.8-037"},{"key":"2024120318500622000_91.8.795.86","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30405-8"},{"key":"2024120318500622000_91.8.795.87","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01310-2"},{"key":"2024120318500622000_91.8.795.88","first-page":":840","article-title":"Apomorphine in the treatment of Parkinson\"s disease: a review","volume":"76","author":"Pessoa","year":"2018","journal-title":"ArqNeuropsiquiatr"},{"key":"2024120318500622000_91.8.795.89","article-title":"ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson disease (ease lid study): a randomized clinical trial","volume":"74","author":"Pahwa","year":"2017","journal-title":"JAMA Neurol"},{"key":"2024120318500622000_91.8.795.90","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.4467"},{"key":"2024120318500622000_91.8.795.91","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-018-0629-0"},{"key":"2024120318500622000_91.8.795.92","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S0140-6736(14)60683-8","article-title":"Long-Term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson\"s disease (PD Med): a large, open-label, pragmatic randomised trial","volume":"384","year":"2014","journal-title":"The Lancet"},{"key":"2024120318500622000_91.8.795.93","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422004"},{"key":"2024120318500622000_91.8.795.94","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-315985"},{"key":"2024120318500622000_91.8.795.95","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008253"},{"key":"2024120318500622000_91.8.795.96","doi-asserted-by":"crossref","first-page":"30396","DOI":"10.1016\/S1474-4422(19)30396-5","article-title":"Apomorphine sublingual film for off episodes in Parkinson\"s disease: a randomised, double-blind, placebo-controlled phase 3 study","volume":"19","author":"Olanow","year":"2020","journal-title":"Lancet Neurol"},{"key":"2024120318500622000_91.8.795.97","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30239-4"},{"key":"2024120318500622000_91.8.795.98","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2016.4703"},{"key":"2024120318500622000_91.8.795.99","doi-asserted-by":"crossref","first-page":"e1849","DOI":"10.1212\/WNL.0000000000005557","article-title":"Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease","volume":"90","author":"Ferreira","year":"2018","journal-title":"Neurology"},{"key":"2024120318500622000_91.8.795.100","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2018.1524876"},{"key":"2024120318500622000_91.8.795.101","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-019-0099-z"},{"key":"2024120318500622000_91.8.795.102","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30044-4"},{"key":"2024120318500622000_91.8.795.103","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27913"},{"key":"2024120318500622000_91.8.795.104","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2019.01.023"},{"key":"2024120318500622000_91.8.795.105","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2018.12.002"},{"key":"2024120318500622000_91.8.795.106","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27602"},{"key":"2024120318500622000_91.8.795.107","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62106-6"},{"key":"2024120318500622000_91.8.795.108","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00389-0"},{"key":"2024120318500622000_91.8.795.109","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1612877"},{"key":"2024120318500622000_91.8.795.110","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27344"},{"key":"2024120318500622000_91.8.795.111","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.01.031"},{"key":"2024120318500622000_91.8.795.112","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.3517"},{"key":"2024120318500622000_91.8.795.113","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30285-6"},{"key":"2024120318500622000_91.8.795.114","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.2421","article-title":"Association of levels of physical activity with risk of Parkinson disease: a systematic review and meta-analysis","volume":"1","author":"Fang","year":"2018","journal-title":"JAMA Netw Open"},{"key":"2024120318500622000_91.8.795.115","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.929"},{"key":"2024120318500622000_91.8.795.116","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907083"},{"key":"2024120318500622000_91.8.795.117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205158"},{"key":"2024120318500622000_91.8.795.118","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2019.10.008"},{"key":"2024120318500622000_91.8.795.119","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27626"},{"key":"2024120318500622000_91.8.795.120","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.0849"},{"key":"2024120318500622000_91.8.795.121","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30403-9"},{"key":"2024120318500622000_91.8.795.122","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27299"},{"key":"2024120318500622000_91.8.795.123","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24820"},{"key":"2024120318500622000_91.8.795.124","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70295-8"},{"key":"2024120318500622000_91.8.795.125","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2017.078"},{"key":"2024120318500622000_91.8.795.126","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2017.09.014"},{"key":"2024120318500622000_91.8.795.127","article-title":"Stem cells: scientific and ethical quandaries of a personalized approach to Parkinson\"s disease","volume":"10","author":"Jankovic","year":"2020","journal-title":"Mov Disord"},{"key":"2024120318500622000_91.8.795.128","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-9007-8_4"},{"key":"2024120318500622000_91.8.795.129","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0507-2"},{"key":"2024120318500622000_91.8.795.130","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-019-0257-7"},{"key":"2024120318500622000_91.8.795.131","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25450"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2019-322338","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T21:51:11Z","timestamp":1733262671000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2019-322338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,23]]},"references-count":131,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,7,20]]},"published-print":{"date-parts":[[2020,8]]}},"alternative-id":["10.1136\/jnnp-2019-322338"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2019-322338","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,23]]}}}